KRAS and non-small cell squamous lung carcinoma: Phase II study of SHR-1210 (anti-PD-1 antibody) combination with apatinib versus pemetrexed and carboplatin in subjects with KRAS mutant stage IV non-squamous non-small cell lung cancer